Compare MITQ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITQ | VRAX |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 2.1M |
| IPO Year | 2019 | 2021 |
| Metric | MITQ | VRAX |
|---|---|---|
| Price | $0.52 | $2.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 107.0K | 27.7K |
| Earning Date | 05-15-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,139,000.00 | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.10 |
| 52 Week High | $1.12 | $13.19 |
| Indicator | MITQ | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 38.23 |
| Support Level | $0.53 | $2.15 |
| Resistance Level | $0.64 | $3.01 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 26.63 | 16.13 |
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.